From: COVID-19 does not influence functional status after ARDS therapy
 | OR | 95% CI | P |
---|---|---|---|
Variables at baseline assessment | |||
Gender | |||
 Male | 1 |  |  |
 Female | 0.42 | 0.19–0.91 | 0.031 |
Age in years | 1.04 | 1.01–1.07 | 0.021 |
BMI | 0.97 | 0.91–1.04 | 0.43 |
Diabetes yes | 0.71 | 0.29–1.72 | 0.45 |
Pulmonary diseases yes | 1.04 | 0.38–2.81 | 0.94 |
HTA yes | 0.92 | 0.44–1.94 | 0.84 |
Min PaO2/FiO2 | 0.99 | 0.99–1.001 | 0.132 |
Max PaO2/FiO2 | 0.996 | 0.99–1.000 | 0.059 |
SOFA baseline | 1.12 | 0.99–1.26 | 0.064 |
COVID-19 | 0.94 | 0.38–2.33 | 0.89 |
Variables during the follow-up | |||
SOFA 5 days ICU | 1.17 | 1.06–1.30 | 0.003 |
ECMO yes | 2.51 | 1.02–6.18 | 0.047 |
Acute Kidney Insufficiency yes | 2.50 | 1.07–5.82 | 0.036 |
CRRT yes | 2.79 | 1.14–6.81 | 0.026 |
Any infection yes | 0.63 | 0.18–2.23 | 0.48 |
Viral infection yes | 0.84 | 0.33–2.11 | 0.71 |
Therapy | |||
 NaCl | 1 |  |  |
 Ilosprost | 1.06 | 0.48–2.32 | 0.89 |
Time ICU days | 1.01 | 0.99–1.03 | 0.24 |